Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus PROCARDIA XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus PROCARDIA XL.
CARDENE vs PROCARDIA XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
20-40 mg orally three times daily.
30-90 mg orally once daily, extended-release tablet.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker